HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pennathur, S. Articles by Coelingh, K. L. Search for Related Content PubMed PubMed Citation Articles by Pennathur, S. Articles by Coelingh, K. L. Agricola Articles by Pennathur, S. Articles by Coelingh, K. L.

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys

MedImmune Vaccines Inc., 297 North Bernardo Avenue, Mountain View, CA 94043, USA

Correspondence
Sridhar Pennathur
pennathurs{at}medimmune.com

Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chimeric bovine/human PIV-3 (b/hPIV-3). These studies also examined the feasibility of substituting Vero cells, cultured in the presence or absence of foetal bovine serum, for foetal rhesus lung-2 (FRhL-2) cells as the tissue culture substrate for the production of bPIV-3 vaccine. The results demonstrated that (i) Vero cell-produced bPIV-3 was as attenuated, immunogenic and efficacious as bPIV-3 vaccine grown in FRhL-2 cells, (ii) plasmid-derived bPIV-3 was as attenuated, immunogenic and efficacious as the biologically derived bPIV-3 and (iii) the b/hPIV-3 chimera displayed an intermediate attenuation phenotype and protected animals completely from hPIV-3 challenge. These results support the use of bPIV-3 vaccines propagated in Vero cells in human clinical trials and the use of b/hPIV-3 as a virus vaccine vector to express foreign viral antigens.

S. Pennathur and A. A. Haller contributed equally to this work.

Published ahead of print on 17 September 2003 as DOI 10.1099/vir.0.19522-0.

This article has been cited by other articles:

				A. Bukreyev, M. H. Skiadopoulos, B. R. Murphy, and P. L. Collins Nonsegmented negative-strand viruses as vaccine vectors. J. Virol., November 1, 2006; 80(21): 10293 - 10306. [Full Text] [PDF]

				R. S. Tang, M. MacPhail, J. H. Schickli, J. Kaur, C. L. Robinson, H. A. Lawlor, J. M. Guzzetta, R. R. Spaete, and A. A. Haller Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys J. Virol., October 15, 2004; 78(20): 11198 - 11207. [Abstract] [Full Text] [PDF]

				M. MacPhail, J. H. Schickli, R. S. Tang, J. Kaur, C. Robinson, R. A. M. Fouchier, A. D. M. E. Osterhaus, R. R. Spaete, and A. A. Haller Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design J. Gen. Virol., June 1, 2004; 85(6): 1655 - 1663. [Abstract] [Full Text] [PDF]